How many clinical trials are tracked for Meningitis?

44 trials are tracked, 5 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Urology Hematology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

Meningitis

Subtypes of Meningitis

Arachnoiditis 1

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Meningitis

44 trials tracked for Meningitis: 22 in phase 3 or 4 and 5 with published results. The most-cited published study has 35 citations.

44Trials tracked

22Phase 3 & 4

0Recruiting

5With published results

Phase distribution

Phase 4 7 Phase 3 15 Phase 2 17 Other / NA 5

Phase 3 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older Completed · 35 cited
Phase 3 Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Completed · 31 cited
Phase 3 Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years Completed · 24 cited
Phase 3 Hypovitaminosis D in Neurocritical Patients Completed · 22 cited
Phase 3 Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine Completed · 8 cited
Phase 4 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier Completed

Show 38 more trials

Phase 4 Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Completed
Phase 4 Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines Completed
Phase 4 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed
Phase 4 Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune® Completed
Phase 4 Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children Completed
Phase 4 Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine Completed
Phase 3 Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation Completed
Phase 3 Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Completed
Phase 3 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers Completed
Phase 3 Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects Completed
Phase 3 Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants Completed
Phase 3 A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India Completed
Phase 3 Immunology and Safety of Menactra® in Children in Saudi Arabia Completed
Phase 3 Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations Completed
Phase 3 Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025) Completed
Phase 3 Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea Completed
Phase 2 Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune® Completed
Phase 2 A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years. Completed
Phase 2 Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine Completed
Phase 2 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers Completed
Phase 2 Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children Completed
Phase 2 Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age Completed
Phase 2 Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth Completed
Phase 2 Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination Completed
Phase 2 Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine Completed
Phase 2 Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam Completed
Phase 2 Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26 Completed
Phase 2 Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older Completed
Phase 2 Dose Comparison Study of Menactra® in US Children Completed
Phase 2 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents Completed
Phase 2 Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents Completed
Phase 2 Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune® Completed
Phase 2 A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers Completed
N/A Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine Completed
N/A Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort Completed
N/A Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children Completed
N/A 36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds Completed
N/A Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine Completed

Showing the 44 most-cited and recently-updated of 44 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Meningitis: what the trials found

Multiple quadrivalent meningococcal conjugate vaccines (MenACWY) demonstrate robust immunogenicity across age groups. In adolescents and adults, MenACWY conjugate vaccines (e.g., Menactra®) induce high seroprotection rates (≥1:8 titers) for serogroups A, C, Y, and W-135, with 4-fold rise rates ranging from 76% to 98% ¹⁵²⁰²¹. Booster vaccination maintains protective titers for at least four years, with geometric mean titers (GMTs) declining but remaining above baseline ². Concomitant administration with Tdap or Pentacel does not impair immune responses to any component ³⁶.

Newer MenACWY tetanus toxoid conjugate vaccines (e.g., MenACYW conjugate) show non-inferior or superior seroresponse rates compared to licensed comparators. In children aged 2–9 years, MenACYW conjugate achieved higher seroresponse for serogroups A (55.4% vs. 47.8%) and Y (91.5% vs. 79.3%) versus MENVEO® ¹⁰. In adolescents and adults, MenACYW conjugate elicited seroresponse rates of 73.8–91.4% across serogroups, outperforming Menactra® for serogroups A (73.8% vs. 54.6%) and W (91.4% vs. 73.4%) ¹⁴. A pentavalent meningococcal vaccine (NmCV-5) targeting serogroups A, C, W, Y, and X induced high geometric mean fold rises (GMFR) for all five serogroups, notably 7111.4 for serogroup X ¹².

Safety profiles of MenACWY conjugate vaccines are favorable. In large phase 3 trials, severe systemic reactions occurred in 13–16% of participants, and serious adverse events were rare (6%) ¹⁷. Local reactions are common but generally mild ⁶¹⁷. A meningococcal polysaccharide vaccine (Menomune®) showed lower seroresponse rates for serogroups A (58.2% vs. 42.5%) and C (77.1% vs. 49.7%) compared to MenACYW conjugate ⁸. Cholecalciferol (vitamin D) supplementation did not significantly reduce hospital length of stay in meningitis patients (p=0.2–0.4) ¹¹.

For the clinician treating this condition

Quadrivalent meningococcal conjugate vaccines (MenACWY) provide high and durable immunogenicity against serogroups A, C, Y, and W-135, with booster responses persisting for at least four years.
Newer MenACYW tetanus toxoid conjugate vaccines demonstrate improved seroresponse for certain serogroups compared to licensed comparators, particularly in children and adolescents.
Safety of MenACWY vaccines is well-established, with low rates of severe adverse events; concomitant administration with other routine vaccines does not compromise immunogenicity.

AI synthesis of 12 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.